MedTrace Logo

Prevalence of Liver Fibrosis and Progression of Liver Fibrosis

NCT01208376 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 195

Last updated 2016-12-20

No results posted yet for this study

Summary

Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.

Conditions

  • HIV Infection and Chronic Alanine Aminotransferase Elevation

Interventions

OTHER

Fibroscan

Fibroscan and Serum Fibrose-marker

Sponsors & Collaborators

  • Swiss HIV Cohort Study

    collaborator NETWORK

  • Helen Kovari-Kramer

    lead OTHER

Principal Investigators

  • 01 Studienregister MasterAdmins · UniversitaetsSpital Zuerich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208376 on ClinicalTrials.gov